Pharmaceutical products; requiring publishing of certain information by manufacturers. Effective date.
SB2024 would create a new set of disclosure requirements for manufacturers of pharmaceutical products in Oklahoma. It defines “ingredient” broadly to include active and inactive components, biological materials such as mRNA and DNA, synthetic materials, and additives. It also defines “manufacturer” and “pharmaceutical product” broadly enough to cover prescription drugs, over-the-counter medications, vaccines, and products intended for research purposes.
The bill requires manufacturers to publish a complete and detailed ingredient list for each product, including chemical and common names, the origin of biological materials, the purpose of each ingredient, and the quantity or concentration of each ingredient. For products using mRNA or other gene-based technology, the disclosure must also identify nucleic acid sequences, their source, and the delivery mechanism, including lipid nanoparticles. The information must be submitted to the State Board of Pharmacy, posted on a manufacturer-maintained website, and included in labeling and marketing materials. The bill also states that disclosure obligations remain unchanged during a national emergency and that individual rights may not be suspended or infringed in that context.
If enacted, SB2024 would add a new statutory disclosure regime in Title 63 of the Oklahoma Statutes governing pharmaceutical product manufacturers. It would impose significant compliance obligations on manufacturers and create enforcement tools including fines, suspension or revocation of distribution rights in Oklahoma, misdemeanor criminal liability for repeated or intentional misrepresentation or omission, private civil actions, class actions, injunctive relief, and whistleblower protections. The State Board of Pharmacy would be required to create a complaint reporting system, while the Legislature would retain exclusive rulemaking authority and the act would control over conflicting laws. The bill is set to take effect January 1, 2027.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears to be strongly regulatory and skeptical of pharmaceutical manufacturers’ current disclosure practices. The bill is framed as a transparency and accountability measure, with an emphasis on public access to ingredient information and enforcement against noncompliance. Because no committee transcript or vote history is provided, there is no documented bipartisan support or opposition in the supplied record.
The main points of contention likely concern the breadth and intrusiveness of the disclosure mandate, especially for vaccines, gene-based products, and research products. Manufacturers may object to requiring public disclosure of detailed ingredient quantities, biological sources, nucleic acid sequences, and delivery mechanisms, as well as to the bill’s penalties, private right of action, and criminal sanctions. Another likely point of dispute is the bill’s emergency clause language, which asserts that disclosure duties and individual rights remain unchanged during a declared national emergency. Supporters would likely emphasize transparency, informed consent, and consumer protection, while opponents may argue the bill could conflict with federal regulation, expose proprietary or sensitive information, and create substantial compliance burdens.